Sol-Gel Signs $27 M Deal for Dermatology Drug Delivery
Complete the form below to unlock access to ALL audio articles.
Sol-Gel Technologies Ltd. has announced that it has entered into a second development and licensing agreement with a leading U.S. pharmaceutical company for the development and commercialization in the U.S. and Canada of a major dermatologic drug.
Under the terms of the new agreement, Sol-Gel will receive $27 million, comprised of an initial non-refundable payment as well as additional license fees and development payments upon the successful completion of various milestones.
The U.S. partner will fund the product’s development. Sol-Gel will be entitled to receive royalties from net sales.
The new agreement follows a similar $25 million deal made with the same company.
“This repeat collaboration reinforces Sol-Gel’s position as a leading player in the development of encapsulation technologies for application to topical drug products,” said Dr. Alon Seri-Levy, co-founder and CEO.